Core Insights - Royal Philips has launched the Zenition 90 Motorized mobile C-arm system aimed at enhancing clinical productivity and care quality for a variety of medical procedures [6][10] - The system features automated workflows and intuitive controls, allowing clinicians to manage C-arm movements effectively, which is expected to save time during procedures [3][10] Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation, with 2023 sales of EUR 18.2 billion and approximately 69,100 employees [13] - The company operates in over 100 countries, providing solutions in diagnostic imaging, ultrasound, image-guided therapy, and personal health [13] Product Features - The Zenition 90 Motorized offers high power (25 kW) for superior image quality and is designed to meet complex vascular and clinical needs [10][11] - Usability studies indicate that 100% of clinicians felt in control of C-arm movements, and 97% believe that workflow features will enhance efficiency [3][4] Sustainability Commitment - Philips has improved the product life of the Zenition 90 Motorized by 25% and enhanced power efficiency by 13% as part of its EcoDesign process [11]

June 17, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 9000 – Zenition 90 Motorized, designed to help clinicians deliver high-quality care to more patients. Philips is partnering with its customers to improve productivity. The new mobile C-arm with expanded capabilities is designed to meet complex vascular needs, but also a range of clinical procedures such as cardia ...

In this regard, Philips' recent launch of the Duo Venous Stent System in a bid to boost its Image-Guided Therapy portfolio remains noteworthy. Expanding Portfolio & Partner Base Aid Diagnosis & Treatment Similarly, PHG also unveiled HealthSuite Imaging, an AI-enabled cloud-based Picture Archiving and Communication System, which offers high-speed remote diagnostic reading, integrated reporting and AIpowered workflow orchestration, enhancing operational efficiency and patient care. Bottom Line The strengtheni ...

The 12-month effectiveness endpoint for primary patency reached 90.2%, which exceeded the performance target goal of 77.3%. The 12-month primary safety endpoint of 98.7% also exceeded the corresponding performance goal of 89%. In addition, quality of life and venous functional assessments that were performed in the VIVID study – including Clinical-Etiology-Anatomy-Pathophysiology (CEAP), Venous Clinical Severity Score (VCSS), Villalta, EQ-5D-3L and VEINES scores – showed sustained improvements compared to b ...

Philips' (PHG) shares have gained 17.6% in the year-to-date period, outperforming the Zacks Medical sector's growth of 4.3%. The company is benefiting from strong momentum in the Diagnosis & Treatment segment on the back of its strengthening Precision Diagnosis portfolio powered by artificial intelligence (AI). The company's latest launch of an AI-enabled cardiovascular ultrasound platform testifies to the aforesaid fact. This FDA 510(k) cleared AI platform combines Philips' EPIQ CVx and Affiniti CVx ultras ...

June 4, 2024 New FDA-cleared AI-enabled applications include the industry's first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery disease and cardio-oncology issues in seconds First fully automated 3D quantification of mitral regurgitation (MR) volumes* designed to provide reproducible, efficient analysis helps clinicians make better-informed decisions for patients with heart valve disease Amsterdam, the Netherlands – Roya ...

May 30, 2024 First to provide helium-free operations in 2018, Philips marks milestone during installation in Puerto Rico Amsterdam, the Netherlands and Bayamón, Puerto Rico – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and world leader in proven helium-free [1] MRI operations, today announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet, which took place in Puerto Rico's Vida Imaging & Breast Center (Bayamón, Puerto Rico). Beyond its economic and sustain ...

May 30, 2024 First to provide helium-free operations in 2018, Philips marks milestone during installation in Puerto Rico Amsterdam, the Netherlands and Bayamón, Puerto Rico – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and world leader in proven helium-free [1] MRI operations, today announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet, which took place in Puerto Rico's Vida Imaging & Breast Center (Bayamón, Puerto Rico). Beyond its economic and sustain ...

Philips (PHG) is leaving no stone unturned to strengthen its footprint in the global medical imaging market on the back of a growing customer base. Per a Mordor Intelligence report, the global medical imaging market is expected to witness a CAGR of 4.9% between 2024 and 2030. Recently, the company announced the wide availability of its VeriSight Pro 3D Intracardiac Echocardiography catheter to several Hong Kong hospitals, thereby expanding clientele for its ICE imaging technology. Philips' VeriSight Pro 3D ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...